We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.65
Bid: 47.75
Ask: 47.90
Change: -0.65 (-1.35%)
Spread: 0.15 (0.314%)
Open: 48.40
High: 48.40
Low: 47.25
Prev. Close: 48.30
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Nanopore funding round and contract win

13 Oct 2020 07:00

RNS Number : 8541B
IP Group PLC
13 October 2020
 

FOR RELEASE ON

13 October 2020

 

 

IP Group plc - Portfolio company Oxford Nanopore Technologies announces £84.4m of additional funding

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that its portfolio company Oxford Nanopore Technologies Ltd ("Oxford Nanopore" or "the Company") has announced that it has raised an additional £84.4 million of new capital from existing and new investors including International Holdings Company (IHC) and RPMI Railpen.

 

The funds will be used to support the rapid acceleration of Oxford Nanopore's commercial and manufacturing operations as well as ongoing innovation in the field of nanopore technology. The round takes the amount raised this year by Oxford Nanopore to £162.1 million, following fund raisings in January and May of £29.3 million and £48.4 million respectively.

 

Following the capital raise, IP Group has a 15.0% undiluted beneficial stake in Oxford Nanopore, valued at £257.7 million. The directors will review the carrying value of Oxford Nanopore, as usual, as part of the Group's Annual Results for 2020 in light of this funding round and all other relevant information.

 

Last week, Oxford Nanopore announced that its LamPORE test is now CE marked for in vitro diagnostic use for the detection of the SARS-CoV-2 virus that causes COVID-19, using its GridION device. Its LamPORE test is now in the process of initial rollouts in the UK, Germany, Switzerland and the United Arab Emirates.

 

The Company previously announced that it had partnered with the UK's Department of Health and Social Care with an initial order of 450,000 LamPORE SARS-CoV-2 tests and the potential to increase to millions of tests per month as indicated by the recent publication of a contract award notice of £112.6m on the TED (Tenders Electronic Daily) website. Further regulatory approvals are being pursued in other countries, including Emergency Use Authorisation in the United States, and with its partner G42 in the United Arab Emirates.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Greg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGPGQPUUPUPGP
Date   Source Headline
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20246:05 pmRNSNotice of AGM, Annual Report
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 20245:48 pmRNSTransaction in Own Shares
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20245:56 pmRNSTransaction in Own Shares
9th Apr 20245:31 pmRNSTransaction in Own Shares
8th Apr 20245:32 pmRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20245:27 pmRNSTransaction in Own Shares
3rd Apr 20245:37 pmRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20247:00 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20245:30 pmRNSTransaction in Own Shares
25th Mar 20246:03 pmRNSTransaction in Own Shares
25th Mar 20248:54 amRNSDirector Declaration
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20245:56 pmRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20245:03 pmRNSDirector Declaration
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNS2023 Annual Results
12th Mar 20245:24 pmRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSCorrection - Holding(s) in Company
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20242:35 pmRNSHolding(s) in Company
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20245:02 pmRNSTransaction in Own Shares
4th Mar 20245:34 pmRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTotal Voting Rights
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20249:00 amRNSNotice of Results
27th Feb 20245:10 pmRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20245:47 pmRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.